NINO RAINUSSO to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications NINO RAINUSSO has written about Xenograft Model Antitumor Assays.
Connection Strength
0.463
-
Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood. J Pathol. 2021 09; 255(1):52-61.
Score: 0.154
-
Generation of patient-derived tumor xenografts from percutaneous tumor biopsies in children with bone sarcomas. Pediatr Blood Cancer. 2019 04; 66(4):e27579.
Score: 0.129
-
Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 2012 Mar; 19(3):212-7.
Score: 0.079
-
Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma. Cancer Res. 2021 01 01; 81(1):199-212.
Score: 0.037
-
Tegavivint and the ?-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. J Natl Cancer Inst. 2019 11 01; 111(11):1216-1227.
Score: 0.034
-
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res. 2018 01 15; 78(2):489-500.
Score: 0.030